• CD47 targeting
Our mission
Our mission

Bring native bispecific therapeutics to patients

Our antibody development roots go deep

CD47 targeting
CD47 targeting

Safe and selective blockade of CD47 on tumors

Safe and selective blockade of CD47 on tumors

CD28 targeting

Safe and selective CD28 co-stimulation

Safe and selective blockade of CD47 on tumors

Who we are
Who we are

Our antibody development roots go deep

Our antibody development roots go deep

Our technology
Our technology, natural bispecific antibodies

Multispecific yet natural

κλ bodies

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow
  • CD28 targeting
  • How it works

Selective CD47 targeting

A bispecific antibody approach

Step 1 – Guided inhibition

Bispecific antibodies bind Tumor Associated Antigen (TAA) with high affinity and block CD47 upon co-engagement at the cell surface. CD47 expressed by TAA-negative healthy cells is not bound or inhibited.

Selective Cd47 Targeting 1

Created with Biorender

Selective Cd47 Targeting 1

Created with Biorender

Step 2 – Enhanced Antibody Dependent Cellular Phagocytosis (ADCP)

ADCP is induced by antibody Fc (human IgG1) binding to Fc receptors on phagocytes (macrophages or dendritic cells). Tumor cell phagocytosis is increased by the blockade of the CD47-SIRPa interaction, the «don’t eat me signal».

Selective Cd47 Targeting

Created with Biorender

Selective Cd47 Targeting

Created with Biorender

Step 3 – Activation of the adaptive immune response

Dendritic Cells and Macrophages process and cross-present tumor antigens to T lymphocytes leading to the induction anti-tumor immunity and potentially durable responses.

Interested by this approach for your own projects? Partner with us

All drawings have been created by BIORENDER

Back

First Patient dosed with NILK-2401 in Phase I clinical trial

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body


Read more

LinkedIn